Login Register Cart 0
Generic placeholder image

Current Gene Therapy

Editor-in-Chief

ISSN (Print): 1566-5232
ISSN (Online): 1875-5631

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

In Press, (this is not the final "Version of Record"). Available online 11 March, 2024
Author(s): Mahmood Araghi, Farshad Gharebakhshi, Fatemeh Faramarzi, Alireza Mafi, Tahoora Mousavi, Mina Alimohammadi* and Hussein Soleimantabar*
Published on: 11 March, 2024

DOI: 10.2174/0115665232283880240301035621

Price: $95

Abstract

Background: Metastatic Triple-negative Breast Cancer (mTNBC) is the most aggressive form of breast cancer, with a greater risk of metastasis and recurrence. Research studies have published in-depth analyses of the advantages and disadvantages of pembrolizumab, and early data from numerous trials suggests that patients with mTNBC have had remarkable outcomes. This meta-analysis compares the data from numerous relevant studies in order to evaluate the safety and efficacy of pembrolizumab monotherapy or combination therapies for mTNBC.

Methods: To identify eligible RCTs, a thorough literature search was carried out using electronic databases. CMA software was utilized to perform heterogeneity tests using fixed and random-effects models.

Results: According to our pooled data, the median Progression-free Survival (PFS) was 2.66 months, and the median overall survival (OS) was 12.26 months. Furthermore, by comparing efficacy indicators between PD-L1–positive and PD-L1–negative groups, a correlation was found between the overexpression of PD-L1 with OS, PFS, and ORR. Patients with PD-L1-positive tumors had a higher response rate, with an ORR of 21.1%, compared to the patients with PD-L1-negative tumors. The ORR for first-line immunotherapy was higher than that of ≥second-line immunotherapy. In addition, pembrolizumab plus combination treatment resulted in a pooled incidence of immune-related adverse events of 22.7%.

Conclusion: A modest response to pembrolizumab monotherapy was detected in the mTNBC patients. Furthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1-- positive status, non-liver/lung metastases, combination therapy, and first-line immunotherapy. Pembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors are PD-L1 positive.

[1]
Yin L, Duan JJ, Bian XW, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 2020; 22(1): 61.
[http://dx.doi.org/10.1186/s13058-020-01296-5] [PMID: 32517735]
[2]
Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28(20): 3271-7.
[http://dx.doi.org/10.1200/JCO.2009.25.9820] [PMID: 20498394]
[3]
Alimohammadi M, Rahimi A, Faramarzi F, et al. Effects of coenzyme Q10 supplementation on inflammation, angiogenesis, and oxidative stress in breast cancer patients: A systematic review and meta-analysis of randomized controlled- trials. Inflammopharmacology 2021; 29(3): 579-93.
[http://dx.doi.org/10.1007/s10787-021-00817-8] [PMID: 34008150]
[4]
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69(5): 363-85.
[http://dx.doi.org/10.3322/caac.21565] [PMID: 31184787]
[5]
Anders CK, Abramson V, Tan T, Dent R. The evolution of triple-negative breast cancer: From biology to novel therapeutics. Am Soc Clin Oncol Educ Book 2016; 35(36): 34-42.
[http://dx.doi.org/10.1200/EDBK_159135] [PMID: 27249684]
[6]
Wang X, Qi Y, Kong X, et al. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. Cancer Lett 2019; 442: 409-28.
[http://dx.doi.org/10.1016/j.canlet.2018.10.042] [PMID: 30419345]
[7]
Ren Y, Song J, Li X, Luo N. Rationale and clinical research progress on PD-1/PD-L1-based immunotherapy for metastatic triple-negative breast cancer. Int J Mol Sci 2022; 23(16): 8878.
[http://dx.doi.org/10.3390/ijms23168878] [PMID: 36012144]
[8]
Qi Y, Zhang L, Wang Z, et al. Efficacy and safety of Anti-PD-1/ PD-L1 monotherapy for metastatic breast cancer: Clinical evidence. Front Pharmacol 2021; 12: 653521.
[http://dx.doi.org/10.3389/fphar.2021.653521] [PMID: 34267656]
[9]
Howard FM, Pearson AT, Nanda R. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2022; 195(1): 1-15.
[http://dx.doi.org/10.1007/s10549-022-06665-6] [PMID: 35834065]
[10]
Abdou Y, Goudarzi A, Yu JX, Upadhaya S, Vincent B, Carey LA. Immunotherapy in triple negative breast cancer: Beyond checkpoint inhibitors. npj. Breast Cancer 2022; 8(1): 1-10.
[PMID: 35013314]
[11]
Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 2021; 23(2): 39.
[http://dx.doi.org/10.1208/s12248-021-00574-0] [PMID: 33677681]
[12]
Larkin J, Sileni CV, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23-34.
[http://dx.doi.org/10.1056/NEJMoa1504030] [PMID: 26027431]
[13]
Larkins E, Blumenthal GM, Yuan W, et al. FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist 2017; 22(7): 873-8.
[http://dx.doi.org/10.1634/theoncologist.2016-0496] [PMID: 28533473]
[14]
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372(4): 320-30.
[http://dx.doi.org/10.1056/NEJMoa1412082] [PMID: 25399552]
[15]
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443-54.
[http://dx.doi.org/10.1056/NEJMoa1200690] [PMID: 22658127]
[16]
Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32(10): 1020-30.
[http://dx.doi.org/10.1200/JCO.2013.53.0105] [PMID: 24590637]
[17]
Rizzo A, Ricci AD, Lanotte L, et al. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: Current knowledge and therapeutic prospects. Expert Opin Investig Drugs 2022; 31(6): 557-65.
[http://dx.doi.org/10.1080/13543784.2022.2009456] [PMID: 34802383]
[18]
Huppert LA, Gumusay O, Rugo HS. Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol 2022; 14.
[http://dx.doi.org/10.1177/17588359221086916] [PMID: 35422881]
[19]
Alimohammadi M, Faramarzi F, Mafi A, et al. Efficacy and safety of atezolizumab monotherapy or combined therapy with chemotherapy in patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des 2023; 29(31): 2461-76.
[http://dx.doi.org/10.2174/0113816128270102231016110637] [PMID: 37921135]
[20]
Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1(9): 1325-32.
[http://dx.doi.org/10.1001/jamaoncol.2015.2756] [PMID: 26270858]
[21]
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol 2018; 15(5): 325-40.
[http://dx.doi.org/10.1038/nrclinonc.2018.29] [PMID: 29508855]
[22]
Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016; 44(2): 343-54.
[http://dx.doi.org/10.1016/j.immuni.2015.11.024] [PMID: 26872698]
[23]
Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol 2022; 12: 919072.
[http://dx.doi.org/10.3389/fonc.2022.919072] [PMID: 35795050]
[24]
Uliano J, Nicolò E, Corvaja C, Salimbeni TB, Trapani D, Curigliano G. Combination immunotherapy strategies for triple-negative breast cancer: Current progress and barriers within the pharmacological landscape. Expert Rev Clin Pharmacol 2022; 15(12): 1399-413.
[http://dx.doi.org/10.1080/17512433.2022.2142559]
[25]
Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17(11): 1558-68.
[http://dx.doi.org/10.1016/S1470-2045(16)30366-7] [PMID: 27622997]
[26]
Gandhi L, Abreu RD, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 2018; 378(22): 2078-92.
[http://dx.doi.org/10.1056/NEJMoa1801005] [PMID: 29658856]
[27]
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396(10265): 1817-28.
[http://dx.doi.org/10.1016/S0140-6736(20)32531-9] [PMID: 33278935]
[28]
Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol 2020; 31(5): 569-81.
[http://dx.doi.org/10.1016/j.annonc.2020.01.072] [PMID: 32278621]
[29]
Cortés J, Lipatov O, Im S-A, et al. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann Oncol 2019; 30: v859-60.
[http://dx.doi.org/10.1093/annonc/mdz394.010]
[30]
Zou Y, Zou X, Zheng S, et al. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: A systematic review and meta-analysis. Ther Adv Med Oncol 2020; 12: 1758835920940928.
[http://dx.doi.org/10.1177/1758835920940928] [PMID: 32874208]
[31]
Simmons CE, Brezden-Masley C, McCarthy J, McLeod D, Joy AA. Positive progress: Current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. Ther Adv Med Oncol 2020; 12: 1758835920909091.
[http://dx.doi.org/10.1177/1758835920909091] [PMID: 33014143]
[32]
Amin M, Sharif S, Asghar W, Sadaf H, Sarfraz A, Sarfraz Z. Atezolizumab and pembrolizumab in triple-negative breast cancer: A meta-analysis. Expert Rev Anticancer Ther 2021; 22(2): 229-35.
[http://dx.doi.org/10.20944/preprints202105.0546.v1]
[33]
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2018; 36(17): 1714-68.
[http://dx.doi.org/10.1200/JCO.2017.77.6385] [PMID: 29442540]
[34]
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378(2): 158-68.
[http://dx.doi.org/10.1056/NEJMra1703481] [PMID: 29562154]
[35]
Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol 2019; 5(8): 1132-40.
[http://dx.doi.org/10.1001/jamaoncol.2019.1029] [PMID: 31194225]
[36]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: b2700.
[http://dx.doi.org/10.1136/bmj.b2700] [PMID: 19622552]
[37]
Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343(oct18 2): d5928.
[http://dx.doi.org/10.1136/bmj.d5928] [PMID: 22008217]
[38]
Alimohammadi M, Rahimi A, Faramarzi F, Navaei AR, Rafiei A. Overexpression of chemokine receptor CXCR4 predicts lymph node metastatic risk in patients with melanoma: A systematic review and meta-analysis. Cytokine 2021; 148: 155691.
[http://dx.doi.org/10.1016/j.cyto.2021.155691] [PMID: 34464923]
[39]
McDermott DF, Atkins MB. PD -1 as a potential target in cancer therapy. Cancer Med 2013; 2(5): 662-73.
[http://dx.doi.org/10.1002/cam4.106] [PMID: 24403232]
[40]
Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs 2022; 31(6): 549-55.
[http://dx.doi.org/10.1080/13543784.2022.2008354] [PMID: 34793275]
[41]
Kumar S, Chatterjee M, Ghosh P, Ganguly KK, Basu M, Ghosh MK. Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes Dis 2023; 10(4): 1318-50.
[http://dx.doi.org/10.1016/j.gendis.2022.07.024] [PMID: 37397537]
[42]
Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016; 34(21): 2460-7.
[http://dx.doi.org/10.1200/JCO.2015.64.8931] [PMID: 27138582]
[43]
Nanda R, Specht J, Dees C, Berger R, Gupta S, Geva R. Abstract P6-10-03: KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC). Cancer Res 2017; 77(S4): P6-10-03.
[44]
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2019; 30(3): 397-404.
[http://dx.doi.org/10.1093/annonc/mdy517] [PMID: 30475950]
[45]
Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Ann Oncol 2019; 30(3): 405-11.
[http://dx.doi.org/10.1093/annonc/mdy518] [PMID: 30475947]
[46]
Sharma P, Lieskovan HS, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168(4): 707-23.
[http://dx.doi.org/10.1016/j.cell.2017.01.017] [PMID: 28187290]
[47]
Huang M, Fasching P, Haiderali A, et al. Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy 2022; 14(13): 1027-41.
[http://dx.doi.org/10.2217/imt-2022-0082] [PMID: 35796042]
[48]
Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat Rev Clin Oncol 2022; 19(2): 91-113.
[http://dx.doi.org/10.1038/s41571-021-00565-2] [PMID: 34754128]
[49]
Rehman MUU, Ali I, Zia H. Pembrolizumab and chemotherapy with radiology comparative analysis in patients with untreated metastatic triple negative breast cancer. Pak J Med Health Sci 2022; 16(07): 796.
[50]
Pauls M, Chia S, LeVasseur N. Current and new novel combination treatments for metastatic triple-negative breast cancer. Curr Oncol 2022; 29(7): 4748-67.
[http://dx.doi.org/10.3390/curroncol29070377] [PMID: 35877237]
[51]
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res 2015; 3(5): 436-43.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0064] [PMID: 25941355]
[52]
Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22(4): 499-511.
[http://dx.doi.org/10.1016/S1470-2045(20)30754-3] [PMID: 33676601]
[53]
Tolaney SM, Kalinsky K, Kaklamani VG, et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase Ib/II study. Clin Cancer Res 2021; 27(11): 3061-8.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-4726] [PMID: 33727258]
[54]
Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One 2016; 11(6): e0157164.
[http://dx.doi.org/10.1371/journal.pone.0157164] [PMID: 27281029]
[55]
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74(19): 5458-68.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-1258] [PMID: 25274032]
[56]
Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, immune checkpoint blockade and the abscopal effect: A critical review on timing, dose and fractionation. Front Oncol 2018; 8: 612.
[http://dx.doi.org/10.3389/fonc.2018.00612] [PMID: 30619752]
[57]
Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol 2019; 20(3): e175-86.
[http://dx.doi.org/10.1016/S1470-2045(19)30026-9] [PMID: 30842061]
[58]
Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol 2018; 36(16): 1611-8.
[http://dx.doi.org/10.1200/JCO.2017.76.2229] [PMID: 29437535]
[59]
Ho AY, Barker CA, Arnold BB, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer 2020; 126(4): 850-60.
[http://dx.doi.org/10.1002/cncr.32599] [PMID: 31747077]
[60]
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. Clin Oncol 2017; 35(15)
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.1008]
[61]
Vinayak S, Tolaney SM, Schwartzberg LS, Mita MM, McCann GA-L, Tan AR. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol 2018; 36(15): 1011.
[62]
Qin G, Wang X, Ye S, et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Nat Commun 2020; 11(1): 1669.
[http://dx.doi.org/10.1038/s41467-020-15364-z] [PMID: 32245950]
[63]
Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Ther Adv Respir Dis 2016; 10(3): 183-93.
[http://dx.doi.org/10.1177/1753465816636557] [PMID: 26944362]
[64]
Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L. Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis. BMJ 2018; 363: k4226.
[http://dx.doi.org/10.1136/bmj.k4226]
[65]
Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol 2019; 5(7): 1008-19.
[http://dx.doi.org/10.1001/jamaoncol.2019.0393] [PMID: 31021376]
[66]
Naing A. Being realistic and optimistic in curing cancer. J Immunother Precis Oncol 2018; 1(2): 53-5.
[67]
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382(9): 810-21.
[http://dx.doi.org/10.1056/NEJMoa1910549] [PMID: 32101663]
[68]
Shah AN, Flaum L, Helenowski I, et al. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer. J Immunother Cancer 2020; 8(1): e000173.
[http://dx.doi.org/10.1136/jitc-2019-000173] [PMID: 32060053]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy